Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C M Rudin

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
British Journal of Cancer|August 15, 2013
A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumoursD W Bowles, W W Ma, N Senzer, et al.
ESMO Open|March 5, 2023
Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancerC M Rudin, A Cervantes, A Dowlati, et al.
Cold Spring Harbor Symposia on Quantitative Biology|March 10, 2001
What keeps a resting T cell alive?C B Thompson, J C Rathmell, K A Frauwirth, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2016
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancerJ C Osorio, A Ni, J E Chaft, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2001
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancerC M Rudin, J Holmlund, G F Fleming, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 17, 2021
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>☆</sup>A-M C Dingemans, M Früh, A Ardizzoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 18, 2025
Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastasesJ A Wilcox, M Y Jeng, S Tischfield, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2022
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomasP Selenica, A Marra, N J Choudhury, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 18, 2020
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomasA J Schoenfeld, H Rizvi, C Bandlamudi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancersJ K Sabari, G C Leonardi, C A Shu, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|August 15, 2013
A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumoursD W Bowles, W W Ma, N Senzer, et al.
ESMO Open|March 5, 2023
Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancerC M Rudin, A Cervantes, A Dowlati, et al.
Cold Spring Harbor Symposia on Quantitative Biology|March 10, 2001
What keeps a resting T cell alive?C B Thompson, J C Rathmell, K A Frauwirth, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2016
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancerJ C Osorio, A Ni, J E Chaft, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2001
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancerC M Rudin, J Holmlund, G F Fleming, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 17, 2021
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>☆</sup>A-M C Dingemans, M Früh, A Ardizzoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 18, 2025
Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastasesJ A Wilcox, M Y Jeng, S Tischfield, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2022
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomasP Selenica, A Marra, N J Choudhury, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 18, 2020
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomasA J Schoenfeld, H Rizvi, C Bandlamudi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancersJ K Sabari, G C Leonardi, C A Shu, et al.
Pageof 5